| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
PI3Kα 3.5 nM (IC50) PI3Kδ 4.6 nM (IC50) mTOR 21.3 nM (IC50)
|
|---|---|
| ln Vitro |
PI3K/mTOR Inhibitor-11 (compound 8o) has been shown to decrease the viability of several human cancer cell lines, including HT29, HCT15, H3122, HeLa, SW620, and H446. Its IC50 values are 0.25, 0.17, 0.29, 0.09, 0.16, and 0.97 μM, respectively[1]. HeLa and SW620 cell colony formation rates are reduced by PI3K/mTOR Inhibitor-11 (0-1.25 μM, 15 days)[1]. HeLa and SW620 cells are arrested at the G0/G1 phases by PI3K/mTOR Inhibitor-11 (0-2.5 μM, 24 h)[1]. In HeLa cells, phosphorylated AKT and S6 proteins are suppressed by PI3K/mTOR Inhibitor-11 (0-2.5 μM, 24 h)[1].
|
| ln Vivo |
Compound 8o, administered intragastrically at doses of 15–60 mg/kg, inhibits the growth of HeLa and SW620 xenograft cancers[1]. Oral bioavailability (76.81%) is demonstrated with PI3K/mTOR Inhibitor-11 (1 mg/kg for iv, 10 mg/kg for po, rats)[1].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: HeLa and SW620 cells Tested Concentrations: 0, 0.15625, 0.625, 1.25 μM Incubation Duration: 24 h Experimental Results: Affected HeLa cells' apoptosis rate from 6.10 to 66.04% in a dose-dependent manner. Western Blot Analysis[1] Cell Types: HeLa Tested Concentrations: 0 , 0.15625, 0.625, 1.25, 2.5 μM Incubation Duration: 24 h Experimental Results: Suppressed the phosphorylated AKT (Ser473 and Thr308) and S6 proteins. |
| Animal Protocol |
Animal/Disease Models: HeLa and SW620 xenograft models of female BALB/c nude mice[1].
Doses: 15, 30, and 60 mg/kg Route of Administration: intragastric (po) administration, daily for 30 days. Experimental Results: The TGIs (tumor growth inhibitions): 80.22, 73.50, and 60.79% in the HeLa xenograft model at doses of 60, 30, and 15 mg/kg, respectively. TGIs: 81.03, 70.81, and 60.58% in the SW620 xenograft model at doses of 60, 30, and 15 mg/kg, respectively. Animal/Disease Models: Rats[1]. Doses: 1 mg/kg for iv, 10 mg/kg for po Route of Administration: iv, po Experimental Results: pharmacokinetic/PK parameters of PI3K/mTOR Inhibitor-11 (compound 8o) dose (mg/kg) T1/2 (h) Cmax (ng/mL) CL (mL/min/kg) F (%) 1 (iv) 17.2 10 (po) 2.6 2995 76.81% |
| References |
| Molecular Formula |
C27H21N7
|
|---|---|
| Molecular Weight |
443.50
|
| Exact Mass |
443.185
|
| CAS # |
2845104-25-6
|
| PubChem CID |
168295564
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
791
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JDUUUKXVZOZLSS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H21N7/c1-16-33-23-14-30-22-6-4-17(19-10-18-8-9-29-26(18)32-12-19)11-21(22)25(23)34(16)20-5-7-24(31-13-20)27(2,3)15-28/h4-14H,1-3H3,(H,29,32)
|
| Chemical Name |
2-methyl-2-[5-[2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[4,5-c]quinolin-1-yl]pyridin-2-yl]propanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 40 mg/mL (90.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4 mg/mL (9.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 40.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2548 mL | 11.2740 mL | 22.5479 mL | |
| 5 mM | 0.4510 mL | 2.2548 mL | 4.5096 mL | |
| 10 mM | 0.2255 mL | 1.1274 mL | 2.2548 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
